Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.38 |
| ▸ | TDP2 | O95551 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3920457 | 0.84 | PTPN1 (0.61) | PTPN1MRGPRX4HTR1ASLC6A2SLC6A4 | |
| SCHEMBL3917425 | 0.84 | PTPN1 (0.47) | PTPN1PTGER1MRGPRX4SLC6A4 | |
| SCHEMBL12056127 | 0.84 | PTPN1 (0.50) | PTPN1MAOBPTGER1HTR6MRGPRX4 | |
| SCHEMBL646919 | 0.84 | PTPN1 (0.47) | PTPN1HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3917446 | 0.84 | PTPN1 (0.47) | PTPN1HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3926449 | 0.83 | PTPN1 (0.43) | PTPN1MAOB | |
| SCHEMBL3917216 | 0.83 | PTPN1 (0.41) | PTPN1MAOB | |
| SCHEMBL647271 | 0.82 | PTPN1 (0.44) | PTPN1MRGPRX4PDCD1CD274 | |
| SCHEMBL4443447 | 0.82 | PTPN1 (0.46) | PTPN1 | |
| SCHEMBL3917279 | 0.82 | PTPN1 (0.46) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084448-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20090181928-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| EP-2038267-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | Novartis AG (CH) | 2009-03-25 | — | — | EP | disclosed |
| WO-2007115058-A2 | THIADIAZOLIDINONE INHIBITORS OF PTPASE | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181928-A1 | ORGANIC COMPOUNDS | PTPRS, PTPRO, PTPRC | PTPN1 21/4885MAOB 1270/4885SLC6A9 4588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.